JP2008513367A5 - - Google Patents

Download PDF

Info

Publication number
JP2008513367A5
JP2008513367A5 JP2007531313A JP2007531313A JP2008513367A5 JP 2008513367 A5 JP2008513367 A5 JP 2008513367A5 JP 2007531313 A JP2007531313 A JP 2007531313A JP 2007531313 A JP2007531313 A JP 2007531313A JP 2008513367 A5 JP2008513367 A5 JP 2008513367A5
Authority
JP
Japan
Prior art keywords
apo2l
antibody
medicament according
trail polypeptide
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007531313A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008513367A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/031907 external-priority patent/WO2006029224A2/en
Publication of JP2008513367A publication Critical patent/JP2008513367A/ja
Publication of JP2008513367A5 publication Critical patent/JP2008513367A5/ja
Pending legal-status Critical Current

Links

JP2007531313A 2004-09-08 2005-09-07 デスレセプターリガンド及びｃｄ２０抗体の使用方法 Pending JP2008513367A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60790904P 2004-09-08 2004-09-08
US66655305P 2005-03-30 2005-03-30
PCT/US2005/031907 WO2006029224A2 (en) 2004-09-08 2005-09-07 Methods of using death receptor ligands and cd20 antibodies

Publications (2)

Publication Number Publication Date
JP2008513367A JP2008513367A (ja) 2008-05-01
JP2008513367A5 true JP2008513367A5 (enExample) 2008-11-13

Family

ID=35788048

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007531313A Pending JP2008513367A (ja) 2004-09-08 2005-09-07 デスレセプターリガンド及びｃｄ２０抗体の使用方法

Country Status (13)

Country Link
US (2) US20090317384A1 (enExample)
EP (1) EP1791864A2 (enExample)
JP (1) JP2008513367A (enExample)
KR (1) KR20070050950A (enExample)
AU (1) AU2005282440A1 (enExample)
BR (1) BRPI0515615A (enExample)
CA (1) CA2577823A1 (enExample)
IL (1) IL181316A0 (enExample)
MX (1) MX2007002855A (enExample)
NO (1) NO20071790L (enExample)
NZ (1) NZ553174A (enExample)
RU (1) RU2007112929A (enExample)
WO (1) WO2006029224A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
BRPI0509201A (pt) 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
GB0524316D0 (en) * 2005-11-29 2006-01-04 Medical Res Council Tumour necrosis factor-related apoptosis-inducing ligands (TRAILs)
BRPI0718413A2 (pt) 2006-10-23 2014-03-11 The Uab Research Foundation Métodos para prever a sensibilidade de uma célula concerosa a um primeiro agente anticâncer, para prever ou monitorar a eficácia de um agente anticâncer, e para determinar uma dose eficaz para um agente anticâncer, kit de detecção, e, sistema de ensaio multiplex
CN101820913A (zh) * 2007-08-09 2010-09-01 第一三共株式会社 在表达含死亡结构域的受体的细胞中诱导细胞凋亡的免疫脂质体
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
WO2011028961A2 (en) 2009-09-04 2011-03-10 Xoma Technology Ltd. Anti-botulism antibody coformulations
WO2011028962A1 (en) * 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody coformulations
AR078161A1 (es) * 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
AR080154A1 (es) 2010-02-10 2012-03-14 Immunogen Inc Anticuerpos cd20 y su utilizacion
WO2012151317A1 (en) * 2011-05-03 2012-11-08 Genentech, Inc. Vascular disruption agents and uses thereof
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
CN107250161A (zh) 2015-01-26 2017-10-13 宏观基因有限公司 包含dr5‑结合结构域的多价分子
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
CN109195620B (zh) * 2016-04-07 2022-06-28 约翰霍普金斯大学 用死亡受体激动剂治疗胰腺炎和疼痛的组合物和方法
CA3045944A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
KR102532779B1 (ko) * 2017-09-08 2023-05-16 한국생명공학연구원 Ddias 억제제 및 사멸 수용체 리간드를 포함하는 암의 예방 또는 치료용 조성물
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
WO2023091887A1 (en) 2021-11-16 2023-05-25 Genentech, Inc. Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
AU704440B2 (en) * 1994-02-04 1999-04-22 Bio Merieux MSRV1 virus and MSRV2 pathogenic and/or infectious agent associated with multiple sclerosis, nucleic acid components and applications of same
CA2225378C (en) * 1995-06-29 2012-04-17 Immunex Corporation Cytokine that induces apoptosis
US6998116B1 (en) * 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US6433147B1 (en) * 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
ATE362982T1 (de) * 1997-01-28 2007-06-15 Human Genome Sciences Inc ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET
US6072047A (en) * 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US20020160446A1 (en) * 2000-11-14 2002-10-31 Holtzman Douglas A. Novel genes encoding proteins having prognostic diagnostic preventive therapeutic and other uses
US20010010924A1 (en) * 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
US6872568B1 (en) * 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
NZ508381A (en) * 1997-03-17 2002-09-27 Human Genome Sciences Inc Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5)
WO1998046643A1 (en) * 1997-04-16 1998-10-22 Millennium Biotherapeutics, Inc. TUMOR NECROSIS FACTOR RECEPTOR RELATED PROTEINS TANGO-63d AND TANGO-63e
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
JPH11162958A (ja) * 1997-09-16 1999-06-18 Tokyo Electron Ltd プラズマ処理装置及びその方法
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
CA2439735A1 (en) * 2001-03-14 2002-09-19 Genentech, Inc. Igf antagonist peptides
EP2348043A1 (en) * 2001-10-02 2011-07-27 Genentech, Inc. APO-2 ligand variants and uses thereof
EP1506285B1 (en) * 2001-11-01 2010-12-08 Uab Research Foundation Combinations of anti-dr5 antibodies and anti-dr4 antibodies and other therapeutic agents
WO2003039486A2 (en) * 2001-11-09 2003-05-15 Idec Pharmaceuticals Corporation Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
WO2004001009A2 (en) * 2002-06-24 2003-12-31 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof

Similar Documents

Publication Publication Date Title
ES2973858T3 (es) Métodos para tratar infecciones cutáneas mediante la administración de un antagonista de IL-4R
Park et al. Eosinophil survival and apoptosis in health and disease
RU2007112929A (ru) Способы применения лигандов рецептора смерти и антител к cd20
US11779631B2 (en) CD47 blockade therapy by HDAC inhibitors
JP2008512479A5 (enExample)
EP3608336B1 (en) Pan elr+ cxc chemokine antibodies
TW201641104A (zh) Ｉｌ－１７抗體之醫藥產品及穩定之液體組合物
EP1921090A4 (en) COMPOSITION OF GENETICALLY MODIFIED ANTIBODY
JP2009519257A5 (enExample)
CN1047035A (zh) 生物应答修饰因子的新颖抗体传递系统
US20240392019A1 (en) Anti-il-36r antibodies for the treatment of neutrophilic dermatoses
JP2015520188A5 (enExample)
US20200237822A1 (en) Compositions and methods for stimulating natural killer cells
CN106170298B (zh) 用于提高抗体稳定性的缓冲液制剂
Amini-Vaughan et al. Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer
EP4268803A1 (en) Stable antibody preparation, preparation method for same, and applications thereof
US20250333522A1 (en) Compositions and methods for treating pain in subjects with rheumatoid arthritis
CN116406290A (zh) 用于治疗慢性炎症性疼痛的抗il-36r抗体
CN101671390B (zh) 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途
CN117924430A (zh) 促进血小板生成的tpor结合肽
CN115666643A (zh) 用于治疗异位性皮肤炎的抗il-36r抗体
WO2015084706A1 (en) Intra-articular formulations and methods for treatment of osteoarthritis
JP2014526440A5 (enExample)
Weigelt et al. Pharmacokinetic evaluation of palifermin for mucosal protection from chemotherapy and radiation
JP4629964B2 (ja) ウシの消化器疾患治療剤